




نیشنل بی کنٹرول پروگرام

GLOBAL TUBERCULOSIS SCENARIO

- Tuberculosis remains a World-wide public health problem. World Health Organization declared TB a **Global Emergency** in 1993 in recognition of its growing influence as a public health problem.

- Nearly two billion people of the global population are infected with *Mycobacterium tuberculosis*.
- More than eight million people develop active tuberculosis every year.
- Globally about two million people die with tuberculosis every year.
- More than 90% of global TB cases and deaths occur in the developing world.
- Seventy-Five percent of TB cases are in the most economically productive age group (15-54 years).

TB: THE LEADING SINGLE INFECTIOUS CAUSE OF DEATH IN SE ASIA




HIGH BURDEN COUNTRIES (GLOBAL TB REPORT)

- o 1. India
- o 2. China
- o 3. South Africa
- o 4. Indonesia
- o 5. Pakistan
- o 6. Bangladesh
- o 7. Philippines
- o 8. Ethiopia
- o .
- o .
- o 22. Afghanistan

FACTS IN PAKISTANI CONTEXT

- Population (millions) estimated to 193
- Pakistan ranks 5th globally among the high tuberculosis burden countries.
- Contributes about 55% of tuberculosis burden in the EMRO.
- The incidence of ss+ve TB cases is 82/100,000/ year and for all types, 181/100,000.
- TB is responsible for 5.1 percent of the total national disease burden in Pakistan.



TB Terminologies

History of drug intake	Sputum Smear result now	Type of patient
<ul style="list-style-type: none"> • Never taken TB drugs in past • Taken TB drugs for less than 1 month in past and never registered in TB-DOTS program 	Smear positive Or Smear negative	New case
Taken full course of TB treatment in past and declared cured or treatment completed	Smear positive	Relapse
<ul style="list-style-type: none"> • New smear positive patient taken TB drugs for 5 months or more • Smear negative patient having taken TB drugs for 2 months or more 	Remains Smear positive Becomes Smear positive	Treatment Failure
Patient registered in program and then interrupted for 2 or more consecutive months	Smear positive	Default
Initially ss+ve pt, on at least two occasions, (one at treatment completion), had,	Smear negative	Cured
<ul style="list-style-type: none"> • SS-ve pt, who received full course of treatment • SS+ve pt, who completed the treatment, but no smear done at treatment end. 	Treatment completed

MANTOUX TEST

- Result after 72 hours
- Induration is measured
- > 10 mm --- Positive
- 6-9 mm --- Doubtful
- < 6 mm --- Negative

PREVENTION OF TB

- BCG Vaccination

CONTROL OF TB

Evolution of global TB strategies

1994

The DOTS Strategy

1. Government commitment
2. Case detection through passive case finding
3. Standardized chemotherapy to all sputum smear positive TB cases of under proper case management conditions
4. Establishment of a system of regular supply of anti-TB drugs
5. Establishment of a monitoring system, for programme supervision and evaluation

2006

The Stop TB Strategy

1. Pursue high-quality DOTS expansion and enhancement
2. Address TB/HIV, MDR-TB and other challenges
3. Contribute to health system strengthening
4. Engage all care providers
5. Empower people with TB and communities
6. Enable and promote research

2014

The End TB Strategy

1. Integrated, patient-centred TB care and prevention
2. Bold policies and supportive systems
3. Intensified research and innovation

1. POLITICAL/ADMINISTRATIVE COMMITMENT

- Perception of TB as a priority problem with real solution
- Government acknowledges importance of disease
- Public commitment to National TB Program (NTP)
- Support for personnel, training, transportation, drugs

2. ACCURATE DIAGNOSIS=SPUTUM MICROSCOPY

- o Identification/cure of smear +ve cases is highest priority of TB control programs

Why?

Smear+ve highly infectious; may infect 10-15 contacts per year; more likely to die if untreated.

3. ADEQUATE SUPPLY OF DRUGS


- o Treatment requires regular doses of combination regimens for >6 months
- o Identification of an adequate supply of appropriate drugs for patients prior to initiation of treatment essential
- o If regimens incomplete, real chance of development of **drug-resistant strains** which are hard or impossible to cure.

4. DIRECTLY OBSERVED TREATMENT

- Why? Many patients don't take medicines regularly, even if excellent health education provided
- Who? All patients... impossible to predict which patient will take medicine (1/3 not adherent)
- What? Observer watches and helps patient swallow tablets
- Where? Anywhere! (home, clinic, work, school, etc)
- Who does it? LHW, community liaisons, teachers, Imams, family members.

Direct observation ensures treatment for entire course with the right drugs, in the right doses, at the right intervals.

DOTS is necessary even when drug supply ensured



Chaulk CP. JAMA 1

5. Systematic Monitoring/Accountability

- Recording system is simple to use, essential, integrated component of DOTS enabling
 - Monitoring of patient outcomes
 - Evaluation of program performance
 - Analysis of epidemiologic data

DRUG RESISTANCE

- Primary/Pre-Treatment
- Secondary/Acquired
- MDR-TB
- XDR-TB

DOTS-PLUS

- DOTS-Plus is a case-management strategy designed to manage MDR-TB using 2nd line drugs within the DOTS strategy and in resource-limited countries

DOTS-Plus means DOTS first

Global TB control targets

MDGS

SDGS

2015: 50% reduction in TB prevalence and death rates by 2015

2015: Goal 6: Combat HIV/AIDS, malaria and other diseases

Target 8: to have halted by 2015 and begun to reverse the incidence...



UN Millennium Development Goals

Indicator 23: prevalence and deaths associated with TB

Indicator 24: proportion of TB cases detected and cured under DOTS

2005: World Health Assembly:

To detect at least 70% of infectious TB cases

To treat successfully at least 85% of detected cases

[The Express Tribune](#) > [Pakistan](#)

Pakistan wins US award for combating tuberculosis

By [APP](#)

Published: March 19, 2016

203SHARES

[Share](#) [Tweet](#) [Email](#)

As a result of concerted efforts, Pakistan has one of the highest rates of success in TB treatment across the world. PHOTO: AFP/FILE

Stop TB Strategy



THE LANCET

"The New Stop TB Strategy and the Global Plan, with the important new developments outlined in this issue, present an ideal opportunity to turn the tide against tuberculosis."

Stop TB Strategy

1 PURSUE HIGH-QUALITY DOTS EXPANSION AND ENHANCEMENT

- a. Political commitment with increased and sustained financing
- b. Case detection through quality-assured bacteriology
- c. Standardized treatment with supervision and patient support
- d. An effective drug supply and management system
- e. Monitoring and evaluation system, and impact measurement

2 ADDRESS TB/HIV, MDR-TB AND OTHER CHALLENGES

- Implement collaborative TB/HIV activities
- Prevent and control multidrug-resistant TB
- Address prisoners, refugees and other high-risk groups and special situations

3 CONTRIBUTE TO HEALTH SYSTEM STRENGTHENING

- Actively participate in efforts to improve system-wide policy, human resources, financial management, service delivery, and information systems
- Share innovations that strengthen systems, including the Private Sector
- Adapt innovations from other fields

4 ENGAGE ALL CARE PROVIDERS

- Public-Public, and Public-Private Mix (PPM) approaches
- International Standards for TB Care (ISTC)

5 EMPOWER PEOPLE WITH TB, AND COMMUNITIES

- Advocacy, communication and social mobilization
- Community participation in TB care
- Patients' Charter for Tuberculosis Care

6 ENABLE AND PROMOTE RESEARCH

- Programme-based operational research
- Research to develop new diagnostics, drugs and vaccines

GEAR UP TO

END TB

VISION

A WORLD FREE OF TB

GOAL

END THE GLOBAL TB EPIDEMIC



GETTING THERE:

Reduction in
number of TB
deaths
(reduction over 2015 level)

Reduction in TB
incidence rate
(reduction over 2015 level)

MILESTONES

TARGETS

SDG*	END
2030	2035
90%	
80%	90%

VISION	A world free of tuberculosis – zero deaths, disease and suffering due to tuberculosis
GOAL	End the global tuberculosis epidemic
MILESTONES FOR 2025	75% reduction in tuberculosis deaths (compared with 2015) 50% reduction in tuberculosis incidence rate (less than 55 tuberculosis cases per 100 000 population) – No affected families facing catastrophic costs due to tuberculosis
TARGETS FOR 2025	95% reduction in tuberculosis deaths (compared with 2015) 90% reduction in tuberculosis incidence rate (less than 10 tuberculosis cases per 100 000 population) – No affected families facing catastrophic costs due to tuberculosis

PRINCIPLES

1. Government stewardship and accountability, with monitoring and evaluation
2. Strong coalition with civil society organizations and communities
3. Protection and promotion of human rights, ethics and equity
4. Adaptation of the strategy and targets at country level, with global collaboration

PILLARS AND COMPONENTS

1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION

- A. Early diagnosis of tuberculosis including universal drug-susceptibility testing, and systematic screening of contacts and high-risk groups
- B. Treatment of all people with tuberculosis including drug-resistant tuberculosis, and patient support
- C. Collaborative tuberculosis/HIV activities, and management of comorbidities
- D. Preventive treatment of persons at high risk, and vaccination against tuberculosis

2. BOLD POLICIES AND SUPPORTIVE SYSTEMS

- A. Political commitment with adequate resources for tuberculosis care and prevention
- B. Engagement of communities, civil society organizations, and public and private care providers
- C. Universal health coverage policy, and regulatory frameworks for case notification, vital registration, quality and rational use of medicines, and infection control
- D. Social protection, poverty alleviation and actions on other determinants of tuberculosis

3. INTENSIFIED RESEARCH AND INNOVATION

- A. Discovery, development and rapid uptake of new tools, interventions and strategies
- B. Research to optimize implementation and impact, and promote innovations

The End TB Strategy : <http://www.who.int/tb/strategy/end-tb/en/>

**WITH TB,
TREATMENT IS MORE THAN JUST
TREATMENT,
RATHER,
TREATMENT IS PREVENTION !**

SPUTUM MONITORING, NEW PATIENTS

Months of treatment					
1	2	3	4	5	6
[=====]	[=====]	[-----]	-----	-----	-----]
	• (sm +)	• if sm +, obtain culture, DST		• if sm +, obtain culture, DST ²	• if sm +, obtain culture, DST ²

Key:

- [=====] Intensive phase of treatment (HRZE)
- [-----] Continuation phase (HR)
- Sputum smear examination

SPUTUM MONITORING, PREVIOUSLY TREATED PATIENTS ON FIRST LINE DRUGS

Months of treatment							
1	2	3	4	5	6	7	8-
[=====]	=====	=====]	[-----]	-----]	-----]	-----]	-----]
		• if sm +, obtain culture, DST		• if sm +, obtain culture, DST			• if sm +, obtain culture, DST

Key:

[=====] Intensive phase: 2 months of HRZES followed by 1 month of HRZE

[-----] Continuation phase with 5 months of HRE

• Sputum smear examination

SCENARIO

- If a lactating mother is diagnosed as a PTB patient, can she breast feed her child???

yes, but face
mask nd all other
protocols & tk Tx nd chils should
not get BCG
vaccine
& INH prophylax